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CurcuminThe transthyretin amyloidoses (ATTR) are devastating diseases characterized by progressive neuropathy and/
or cardiomyopathy for which novel therapeutic strategies are needed. We have recently shown that
curcumin (diferuloylmethane), the major bioactive polyphenol of turmeric, strongly suppresses TTR ﬁbril
formation in vitro, either by stabilization of TTR tetramer or by generating nonﬁbrillar small intermediates
that are innocuous to cultured neuronal cells.
In the present study, we aim to assess the effect of curcumin on TTR amyloidogenesis in vivo, using a well
characterized mouse model for familial amyloidotic polyneuropathy (FAP). Mice were given 2% (w/w) die-
tary curcumin or control diet for a six week period. Curcumin supplementation resulted in micromolar
steady-state levels in plasma as determined by LC/MS/MS. We show that curcumin binds selectively to the
TTR thyroxine-binding sites of the tetramer over all the other plasma proteins.
The effect on plasma TTR stability was determined by isoelectric focusing (IEF) and curcumin was found to
signiﬁcantly increase TTR tetramer resistance to dissociation. Most importantly, immunohistochemistry
(IHC) analysis of mice tissues demonstrated that curcumin reduced TTR load in as much as 70% and lowered
cytotoxicity associated with TTR aggregation by decreasing activation of death receptor Fas/CD95, endoplas-
mic reticulum (ER) chaperone BiP and 3-nitrotyrosine in tissues. Taken together, our results highlight the
potential use of curcumin as a lead molecule for the prevention and treatment of TTR amyloidosis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Amyloidosis constitute a large group of acquired or hereditary dis-
orders caused by extracellular deposition of abnormal insoluble ﬁbrils
composed of misfolded proteins or fragments thereof, which can
damage tissue architecture and function, thus causing disease [1,2].
Nearly 30 different unrelated proteins, which share high content of
lamellar cross β-sheet structure, are reported to be capable of forming
amyloid ﬁbrils in vivo, though they are associated with clinically dis-
tinct conditions [1,2].
Human transthyretin (TTR), carrier of virtually all of the retinol bind-
ing protein (RBP) in blood and about 15% of total thyroxine (T4) in
plasma, is associated with different forms of amyloidosis. That is the
case of senile systemic amyloidosis (SSA), a late onset disease in which
non-mutated TTR forms amyloid that deposits preferentially in theia Molecular e Celular, Rua do
351 226074900; fax: +351
).
rights reserved.heart, affecting about 25% of individuals over 80 years, and the case of fa-
milial amyloidotic polyneuropathies (FAP) and cardiomyopathies (FAC)
in which single amino acid substitutions resulting from single point mu-
tations in the TTR gene result in deposition of amyloid aggregates in pe-
ripheral and autonomic nervous systems and heart, respectively [3,4].
Regarding hereditary TTR-related amyloidosis, since the ﬁrst report
describing the TTR V30M mutant, the most common among FAP
patients [5], more than one hundred TTR variants have been found to
cause TTR amyloidosis (amyloidosismutations.com). The amyloidogenic
potential of the TTR variants has been related to the decrease of protein
tetramer conformational stability [6], which leads to its dissociation
into partially unfolded non-native monomeric species, the rate-
limiting step for the process of amyloid ﬁbril formation associated to
neurodegeneration and cell death [7]. Moreover, studies using a combi-
nation of polyacrylamide gel electrophoresis (PAGE) and isoelectric
focusing (IEF) under semi-dissociating conditions have shown that
amyloidogenic TTR tetramers present a greater tendency to dissociate
comparedwith wild-type (WT) TTR [8]. It has been shown that binding
of T4 to TTR efﬁciently inhibits TTR ﬁbrillogenesis in vitro and does so by
stabilizing the tetramer against dissociation, thus preventing the
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mation [9]. Accordingly, it has been proposed that small aromatic mol-
ecules might act analogously by binding preferentially to the central
hydrophobic channel and stabilizing the native state of TTR over its dis-
sociative transition state [7]. Very recently, our group reported that
curcumin (diferuloylmethane), a naturally occurring polyphenol, com-
petes with T4 for the binding to TTR and inhibits different steps of the
process of TTR amyloid ﬁbril formation in vitro [10]. In the current
work, we present the in vivo effects of curcumin using a well character-
ized FAP mice model.
2. Materials and methods
2.1. Ethics statement
All the experiments described herein were approved by the
Portuguese General Veterinarian Board (authorization number 024976
from DGV-Portugal) and are in compliance with national rules and the
European Communities Council Directive (86/609/EEC), for the care
and handling of laboratory animals.
2.2. Transgenic mice
Seven month-old transgenic mice for human TTR V30M in a TTR
null background [11], labeled as hTTR V30M mice, were fed either
standard mouse chow (controls, n=10) or standard mouse chow
containing 2% (w/w) curcumin (Sigma-Aldrich, St. Louis, MO, USA)
(treated, n=10) over 6 weeks. After the treatment period, animals
were sacriﬁced following anesthesia with ketamine/xylazine and
blood samples were collected. Plasma was separated by centrifuga-
tion and stored at−20 °C prior to analysis. Mice tissues, in particular
whole gastrointestinal tract (GI), including esophagus, stomach, colon
and duodenum, were immediately excised and frozen at −80 °C or
ﬁxed in 4% neutral buffered formalin and embedded in parafﬁn for
light microscopy techniques.
2.3. Analytical procedure and sample preparation for the determination
of curcumin in mice plasma
The frozen plasma samples were thawed at room temperature. Then,
0.3 ml of 134 U/mlβ-glucuronidase solution in sodiumacetate buffer (pH
5.0)was added to 100 μl of each plasma. Themixtureswere vortexed and
incubated at 37 °C for 1 h. The buffered plasmas were extracted with
2 ml of ethyl acetate by vortex mixing for 2 min. After centrifugation at
2000 rpm for 2 min, the upper organic layer was removed into a clean
microcentrifuge tube and evaporated to dryness under nitrogen stream.
The extracts were re-suspended in 200 μl of methanol.
2.3.1. Chromatographic procedure
The HPLC system consisted of a variable loop Accela autosampler, an
Accela 600 LC pump and an Accela 80 Hz PDA detector (Thermo Fisher
Scientiﬁc, San Jose, CA, USA). Analyses were carried out in using a
Supelco Discovery® C-18 (15 cm×2.1 mm×5 μm) column (Agilent
Technologies, Waldbronn, Germany). The compounds were separated
using a gradient elution program at a ﬂow rate of 0.2 ml min−1, at
25 °C. The mobile phases consisted in water:acetonitrile (90:10, v/v)
(A) and acetonitrile (B), both with 0.1% of formic acid. The following
linear gradient was applied: 0–20 min: 0–100% B; 20–23 min: 100% B;
23–30 min: 100–0% B; followed by re-equilibration of the column for
10 minutes before the next run. Single online detection was carried out
in DAD detector, at 280 nm, and UV spectra in a range of 210–600 nm
were also recorded.
2.3.2. ESI–MSn analysis
The HPLC system was coupled to a LCQ Fleet ion trap mass spec-
trometer (Thermo Finnigan, San Jose, CA, USA) with an ESI sourceand operating in negative mode. The spray voltage was 5 kV and
capillary temperature 300 °C. The capillary and tune lens voltages
were set at −28 V and −115 V, respectively. CID-MSn experiments
were performed on mass-selected precursor ions in the range of m/z
100–1000. The scan time was equal to 100 ms and the collision ener-
gy was optimized between 15 and 40 (arbitrary units), using helium
as collision gas. Data were acquired using Xcalibur® data system
(Thermo Finnigan, San Jose, CA, USA).
2.3.3. Calibration curve
The curcumin calibration curvewas obtained taking into account the
possibility of a non-complete efﬁcient extraction. Thus, six different
concentrations of curcumin standards were added to plasma control
samples in the range 0.7–14 μM. The samples were then extracted
using the methodology above described. The injection in HPLC, under
the same chromatographic conditions, gave a linear regression between
the peak area and concentration (expressed as μg ml−1) with R2=
0.982, intercept of 948224 and slope of 2.87×106. The detection range
was established from 0.36 to 1.20 μg ml−1.
2.4. Determination of TTR levels in mice plasma by sandwich enzyme-linked
immunosorbent assay (ELISA)
The concentration of plasma TTR was determined by ELISA. Brieﬂy,
96-well plates (Nunc, Roskilde, Denmark) were coated overnight
at 4 °C, with rabbit anti-human TTR polyclonal antibody (Abcam,
Cambridge, UK). After blocking and washes, TTR standards
(2–25 ng/ml) and the diluted mice plasma were applied to different
wells in triplicate and incubated. Following sheep anti-human TTR
was added and incubated for one hour (Abcam, Cambridge, UK). After
washing, anti-sheep conjugated alkaline phosphatase was added.
p-Nitrophenyl phosphatase was employed in color development. The
absorbancewasmeasured at 405 nm in aMultiskan® Ascentmicroplate
spectrophotometer (Thermo Electron Instruments). Data were ﬁtted to
2nd-order polynomial (quadratic equation).
2.5. Thyroxine (T4) binding gel electrophoresis
Five microliters of plasma from curcumin treated mice and from
controls (non-treated mice) were incubated with [125I]-T4 (speciﬁc
radioactivity 1250 μCi/µg; Perkin–Elmer, MA, USA). The plasma pro-
teins were then separated by native PAGE [12]. The gel was dried,
subjected to phosphor imaging (Typhoon 8600; Molecular Diagnos-
tics, Amersham Biosciences), and analyzed using the ImageQuant
program version 5.1.
2.6. Isoelectric focusing (IEF) in semi-dissociating conditions
Thirty microliters of mice plasma from treated and non-treated
animals were subjected to native electrophoresis (PAGE). The TTR
gel band was excised and applied to a semi-dissociating (4 M urea)
pH 4–6.5 IEF gel run for 6 hours at 1200 V [12]. Proteins were stained
with Coomassie Blue. The gels were scanned and subjected to densi-
tometry analysis using the ImageQuant program version 5.1.
2.7. Immunohistochemistry
Tissue sections (5 mm thick) were deparafﬁnated in histoclear
and dehydrated in a descent alcohol series. Endogenous peroxidase
activity was inhibited with 3% hydrogen peroxide/ 100% methanol,
and sections were blocked in 4% fetal bovine serum and 1% bovine
serum albumin in PBS. The primary antibodies and the respective di-
lutions used were: rabbit polyclonal anti-TTR (1:1000) (Carpinteria,
CA, USA), goat polyclonal anti-BiP (1:50) and rabbit polyclonal
anti-Fas (1:200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
rabbit polyclonal anti-3-nitrotyrosine (1:500) (Chemicon, Temecula,
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overnight at 4 °C. Antigen visualization was performed with the
biotin–extravidin peroxidase kit (Sigma-Aldrich, St. Louis, MO, USA)
using hydrogen peroxide and diaminobenzidine as substrate and
chromogen, respectively. Immunohistochemistry analysis was carried
out independently by two investigators unaware of the origin of the test-
ed tissue sections. Semi-quantitative immunohistochemical (SQ-IHC)
analysis was performed using Image-Pro Plus version 5.1 software. This
application enables themeasurement of the area occupied by pixels cor-
responding to the immunohistochemical substrate's color that is normal-
ized relatively to the total area. Each slide was analyzed in ﬁve different
representative areas.
2.8. Total protein extracts and Western blot analysis
Mice tissues (approximately 5 mg), in particular stomach and
colon, were homogenized on ice in a small glass rod homogenizer
with 300 μl of lysis buffer containing 5 mM EDTA, 2 mM EGTA,
20 mM MOPS, 1% Triton X-100, 1 mM PMSF and Protease Inhibitor
Mix (GE Healthcare). After centrifugation (14,000 rpm for 20 min at
4 °C) protein concentration in the supernatant was determined by
the Bradford protein assay (Bio-Rad, CA, USA). Fifty micrograms of
total protein from each tissue were separated on 15% SDS–PAGE
and transferred onto a nitrocellulose Hybond-C membrane using a
Mini Trans-Blot Cell (Bio-Rad) system. The primary antibodies and
the respective dilutions used were: rabbit polyclonal anti-TTR
(1:1000) (Carpinteria, CA, USA), rabbit polyclonal anti-BiP (1:1000)
(Abcam, Cambridge, UK) and mouse polyclonal GAPDH (1:1000)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Detection was
performed with ECL® (GE Healthcare, Buckinghamshire, UK). Quanti-
ﬁcation of blots was performed with a Bio-Rad ChemiDoc XRS system
using the IMAGELAB software, and immunosignals were normalized
with GAPDH expression. Results are presented as normalized densi-
ty±SD.
3. Results
3.1. Dietary curcumin administration results in stable levels in plasma
In the present study, we aimed to study the effect of subchronic
supplementation of curcumin at an early stage of the pathogenesis,
because previous in vitro studies demonstrated that curcumin in-
hibits TTR aggregation and TTR aggregates deposition and associated
cytotoxicity begin prior to amyloid formation. We used the hTTR
V30M mice that present deposition of non-ﬁbrillar mutant TTR
starting at approximately 6 months of age; TTR amyloid ﬁbrils are
typically detected after 1 year of age or later and the deposition oc-
curs mainly at the gastrointestinal tract.
Mice were fed ad libitum a diet consisting of standard mouse chow
with 2% (w/w) curcumin. This intermediary dosage was selected
based upon available in vivo reports [13–15]. Quantiﬁcation of TTR
in mice plasma from untreated and curcumin treated hTTR V30M
mice revealed no signiﬁcant difference between the two groups
(389±172 μg TTR/ml and 441±96 μg TTR/ml, respectively), indicat-
ing that curcumin treatment did not interfere with TTR plasma levels
in vivo.
We measured curcumin plasma levels by LC/MS/MS analysis. Mice
fed with curcumin diet reached a steady-state plasma concentration
of 21.4±3.6 μM total curcumin (unconjugated and metabolites) at
the end of the treatment period. No curcumin was detected in
untreated mice plasma. As expected from previous studies using sim-
ilar or higher doses in vivo, dietary supplementation of curcumin was
well tolerated and non-toxic [14,16]. Weight gain in the control and
curcumin-fed group was identical over the 6-weeks period of treat-
ment (results not shown). No liver toxicity was detected by histolog-
ical evaluation of hematoxylin and eosin stained liver sections.3.2. Curcumin selectively binds to TTR in plasma
The interaction of curcumin with TTR in vivo was conﬁrmed by
analysis of plasma, from treated and control mice, after incubation
with radiolabelled T4 ([125I]-T4) and separation of plasma T4-binding
proteins by gel electrophoresis in native conditions and visualization
after autoradiography of the dried gel as can be seen in Fig. 1A. Phos-
phor imaging analysis of the gels (Fig. 1A) showed that, in control
mice, three main proteins bound T4: the main binding protein was
TTR (62.48%±12.46 of total T4) followed by albumin (26.96%±
6.52) and TBG (T4 binding globulin, 10.56%±7.41). The results
showed less [125I]-T4 binding to plasma TTR (36.19%±12.21) from
curcumin treated mice, indicating that curcumin mediated a potent
inhibition (42% decrease) of binding of T4 to TTR. Displacement of
[125I]-T4 from plasma TTR by curcumin resulted in more intense
TBG bands due to the higher binding afﬁnity of T4 to TBG than to
albumin.
3.3. Curcumin treatment increases plasma TTR resistance to dissociation
The effect of curcumin on plasma TTR tetramer stabilization was in-
vestigated by IEF in the presence of 4 M urea. Plasma samples from
treated hTTR V30M and control mice were compared concerning band
patterns and tetramer/total protein ratios. Under the tested conditions,
plasma TTR presented a characteristic band pattern composed ofmono-
mer, an oxidizedmonomer and several lower pI bands corresponding to
different forms of tetramers (Fig. 1B). The results showed that mice
treated with curcumin presented a signiﬁcant increase of TTR stability
as evidenced by the higher tetramer/total protein ratio (0.45) when
compared to control animals (0.29) (Fig. 1B).
3.4. Curcumin decreases non-ﬁbrillar TTR deposition and associated
biomarkers
The effect of curcumin on non-ﬁbrillar TTR deposition in different
tissues was investigated by semi-quantitative immunohistochemical
analysis (SQ-IHC) and Western blotting. At the end of treatment,
mice were 8.5 month-old and, as expected at this age, control mice
displayed widespread TTR staining along the gastrointestinal (GI)
tract. In contrast, curcumin treated mice exhibited signiﬁcant reduc-
tion of TTR load in all GI tract organs analyzed. In stomach, the main
organ of TTR deposition in hTTR V30M mice, we detected a decrease
of approximately 58% of TTR aggregates as can be seen in the repre-
sentative IHC images and respective quantiﬁcation (Fig. 2A). These
results were further conﬁrmed by Western blot analysis of TTR levels
after normalization to GAPDH signal intensities.
Moreover, the highest reduction in TTR staining was obtained in
the intestine, particularly in colon (86% decrease) (Fig. 3A). We next
searched for activation of several tissue markers previously associat-
ed with TTR extracellular deposition [17–19], including ER-resident
chaperone BiP, Fas receptor (CD95) and 3-nitrotyrosine.
By semi-quantitative IHC, we found a decrease of approximately
75% of the ER chaperone BiP in the stomach of curcumin treated
mice, as compared to the untreated control group (Fig. 2A). Results
were conﬁrmed by Western blot of stomach lysates (Fig. 2B). Like-
wise, a signiﬁcant decrease of BiP immunoreactivity was found in
colon (63% decrease) as can be seen in Fig. 3A. BiP quantiﬁcation by
Western blot analysis colon of lysates corroborated the IHC results
(Fig. 3B).
We also investigated the engagement of death receptors on the
cell surface typically up-regulated in tissues from patients affected
with TTR-associated amyloidoses, in particular Fas receptor (CD95).
Immunostaining analysis of mice tissues showed that treated mice
presented reduced levels of Fas in the stomach and colon (Figs. 2A
and 3A, respectively).
Fig. 1. Curcumin binds to TTR in plasma and increases TTR resistance to dissociation. (A) Representative PAGE analysis of [125I]-T4 distribution among T4 binding proteins after
incubation with plasma from treated and non-treated hTTR V30M mice. Different plasma T4 binding proteins are indicated. The histogram shows percentage of total bound
[125I]-T4 to each plasma T4 binding protein. (B) Plasmas from mice treated with curcumin and controls were subjected to isoelectric focusing analysis (IEF) under
semi-dissociating conditions. Different TTR molecular species are indicated. The histogram shows TTR tetramer/total TTR bands ratio obtained after densitometry analysis of IEF
gels for both treated and untreated groups of 10 animals each (⁎⁎Pb0.01).
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marker of peroxynitrite-mediated tissue injury in TTR amyloidosis
[17]. Thus, we next searched for activation of the 3-nitrotyrosine
(3-NT) by IHC and found a decrease of 64% and 78%, respectively, in
the stomach and colon of curcumin treated mice, as compared to
the untreated control group (Figs. 2A and 3A, respectively).
4. Discussion
There are multiple lines of compelling evidence indicating that
curcumin, the main biologically active phytochemical of Curcuma
longa, can be useful for the prevention and treatment of several
types of neurodegenerative diseases.
Curcumin is capable of dose-dependently inhibit Aβ aggregation and
disaggregate pre-formed Aβ ﬁbrils [20] and this seems to depend on
ﬁbril-related conformational structure rather than primary sequence
[21]. In addition, curcumin blocks Aβ42 oligomer toxicity and increases
cell viability in SH-SY5 human neuroblastoma cells [21]. When fed to
transgenic mouse models of Alzheimer's disease curcumin has been
shown to cross the blood–brain barrier (BBB), label plaques and reduce
amyloid levels and plaque burden, resulting in reduced cognitive deﬁcits
and neuroinﬂammation [21,22]. Beyond AD, oral curcumin efﬁcacy has
been recently shown in a knock-inmousemodel of Huntington's disease,
receiving a curcumin diet since conception until 4.5 months of age. At
the end of the treatment, mice presented decreased huntingtin aggre-
gates, improvement of neuropathology and transcriptional deﬁcits and
partial behavioral improvement [23].
With regard to TTR amyloidosis, we and other authors reported
that curcumin binds to WT and mutant TTR and increases its confor-
mational stability both in vitro and ex vivo [10,24]. We have also char-
acterized the effects of curcumin on TTR aggregation in vitro [10]. We
demonstrated that curcumin induces TTR oligomerization into a ho-
mogeneous population of small spherical aggregates as assayed by
transmission electron microscopy (TEM) and dynamic light scattering(DLS). When incubated with Schwannoma cells, curcumin-generated
oligomers were shown to decrease caspase-3 activation as compared
with “on-pathway” intermediates, thus indicating that curcumin redi-
rects TTR aggregation cascade. Moreover, curcumin was also found to
act as amyloid ﬁbril disruptor in vitro.
Herein, we investigated the in vivo effects of curcumin on TTR depo-
sition in a FAP mice model by subchronic oral supplementation with
curcumin. A wide range of doses (0.05%–5% w/w in chow) have been
used to test curcumin efﬁcacy in different mouse models of aging,
neuroinﬂammation and tumorigenesis [25]. We chose a dosage (2%)
that has been proven to be safe and is well within the range of those for-
merly reported to produce steady-state levels of curcumin in plasma
and gastrointestinal mucosa in vivo [16,26].
In the present study, mice fed with curcumin reached a relatively
high plateau concentration of 21.4±3.6 μM in plasma that resulted in
a potent competition with T4 (42%) for the binding to TTR. In addition,
selective binding of curcumin to the largely unoccupied T4 binding
sites signiﬁcantly inhibited tetramer dissociation into non-native mo-
nomeric intermediaries under semi-dissociating conditions. This observa-
tion is consistent with one of the most likely therapeutic approaches for
the disease, by which small molecule interactions at the weaker dimer–
dimer interface might stabilize the native state of TTR over the dissocia-
tive transition state, thus preventing amyloidogenesis cascade from
beginning [7]. Indeed, we further demonstrate that curcumin chronic ad-
ministration signiﬁcantly lowers TTR load in tissues, particularly along the
gastrointestinal tract.
In FAP, intertwined activation of pathways leading to apoptosis,
ER-mediated stress response and oxidative damage have been ob-
served in tissues presenting extracellular TTR deposition but not spe-
cialized in TTR synthesis [27]. Our results indicate signiﬁcant decrease
of Fas-death receptor, ER-resident chaperone BiP and 3-nitrotyrosine
levels in the vicinity of the deposits, which is in accordance with
curcumin inhibitory effect on TTR aggregation and suggestive of re-
duction of cytotoxicity and phenotype recovery/tissue improvement.
Fig. 2. Curcumin supplementation decreases TTR deposition and associated biomarkers in stomach of hTTR V30M mice. (A) Representative immunohistochemistry analysis of TTR,
BiP, Fas and 3-nitrotyrosine in colon of hTTR V30M mice fed with curcumin (right panels) and age-matched controls (left panels); 20× magniﬁcation. Histogram: quantiﬁcation of
immunohistochemical images is represented as percentage of occupied area±SD (⁎⁎⁎Pb0.005). (B) Representative anti-BiP and anti-TTR Western blots of stomachs from TTR
V30M mice treated with curcumin and non-treated mice. Histogram: normalized BiP/GAPDH and TTR/GAPDH density quantiﬁcations±SD (⁎Pb0.05; ⁎⁎Pb0.01).
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directly modulating the TTR misfolding cascade, we speculate that other
important pharmacological aspects of curcumin may actually potentiate
its anti-amyloidogenic/neuroprotective effects in vivo. It is widely accept-
ed that inﬂammation and oxidative impairment play a key role in the
process of amyloid deposition, and therapies that speciﬁcally block
oxidative-inﬂammatory signaling pathways may mitigate amyloid pa-
thology [28,29]. Actually, curcumin treatment has been proven effective
in inhibiting several mediators of inﬂammation, including interleukin
(IL)-1β, phospho-c-Jun NH2-terminal kinase (pJNK), nitrotyrosine and
inducible nitric-oxide synthase (iNOS) while reducing Aβ plaque depo-
sition in ADmodels [30,31]. Furthermore, it has been reported that nat-
ural curcuminoids restore Aβ phagocytosis by AD peripheral bloodmononuclear cells (PBMCs), thus suggesting an immune-mediated ap-
proach to stimulate uptake and clearance of Aβ peptide by AD patients
innate immune cells [32,33] .
Over the past decades, different non-invasive therapeutic measures
have been suggested against TTRamyloidosis. Smallmolecules presenting
structural complementarity to the T4 binding sites within TTR, including
non-steroidal anti-inﬂammatory drugs (NSAIDs) such as ﬂufenamic
acid and diﬂunisal, and its derivatives, have been proposed for FAP
treatment by acting as TTR kinetic stabilizers [12,34]. Recently, tafamidis
meglumine, a potent inhibitor of TTR dissociation, (Fx-1006A) has com-
pleted Phase II/III trials for the treatment of FAP [35].
Given the clinical and genetic heterogeneity of TTR amyloidosis, it
has become increasingly clear that combination therapiesmay improve
Fig. 3. Curcumin supplementation decreases TTR deposition and associated biomarkers in colon of hTTR V30Mmice. (A) Representative immunohistochemistry analysis of TTR, BiP,
Fas and 3-nitrotyrosine in stomach of hTTR V30M mice fed with curcumin (right panels) and age-matched controls (left panels); 20× magniﬁcation. Histogram: quantiﬁcation of
immunohistochemical images is represented as percentage of occupied area±SD (⁎⁎⁎Pb0.005). (B) Representative anti-BiP and anti-TTR Western blots of colon from hTTR V30M
mice treated with curcumin and non-treated mice. Histogram: normalized BiP/GAPDH and TTR/GAPDH density quantiﬁcations±SD (⁎Pb0.05; ⁎⁎Pb0.01).
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duce TTR amyloidogenicity. Recently, our laboratory has reported that
epigallocatechin-3-gallate (EGCG), the main polyphenol constituent of
green tea, inhibits TTR ﬁbrillogenesis by a different mode of interaction
that does not encompass the hydrophobic T4 binding pockets [36,37].
The crystal structure of the TTR-EGCG complex indicated three novel
binding sites for EGCG on TTR, all located at the molecule surface. The
structural data suggested a more rigid binding of EGCG to the binding
site located in a region of the TTR tetramer that allows contact of
EGCG with both TTR dimers, thereby stabilizing the TTR tetramer [38].
The other two binding sites are found at different monomers in the
TTR molecule and may be involved in the oligomerization of TTR tetra-
mers, resulting in the formation of small “off-pathway” aggregates
[36,38] that are innocuous to neuronal cells [10,38]. Moreover, Kristen
and colleagues further supported these observations by showing an in-
hibitory effect of green tea and/or green tea extract on the progression
of cardiac TTR amyloidosis [39].Since both curcumin and EGCG are able to redirect TTR misfolding
and cytotoxicity, although by different molecular mechanisms of ac-
tion, it seems plausible to speculate whether a combined treatment
using both compounds might synergistically increase their clinical
beneﬁcial effects on TTR pathology.
While curcumin appears to be non-toxic and well-tolerated in
humans, even in clinical trials for the treatment of inﬂammatory
bowel disease and colorectal cancer [25], some concerns regarding
its poor oral bioavailability have been raised [40].
The average curcumin peak serum concentration achieved in a
Phase I clinical trial, where 4–8 g/day of curcumin were orally admin-
istrated for 3 months, was 0.41–1.75 μM (lower than that obtained in
our study) [41]. In order to increase those levels and the biological ac-
tivity of curcumin, several strategies have been proposed. Some are
directed towards the development of curcumin structural analogs,
and others to different routes of administration or delivery systems,
namely by the use of nanoparticles or liposomes. The use of adjuvants
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been tested. That is the case of piperine, a known inhibitor of hepatic
and intestinal glucuronidation, which when administrated concomi-
tantly with curcumin results in 2000% increase bioavailability in
humans [41]. Even though, more and longer studies are necessary to
conﬁrm the effectiveness of such strategies. Currently, the efﬁcacy
of curcumin on Alzheimer's disease (AD) progression is being tested
by clinical trials for Mild Cognitive Impairment (MCI) or mild
Alzheimer's Disease (clinicaltrials.gov) using doses up to 6 g/day.
In conclusion, the present study demonstrated that dietary curcumin
modulates TTR amyloidogenicity in vivo, and points towards the poten-
tial use of curcumin as a leadmolecule for the design of newTTR amyloid
inhibitors.
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